SAB Biotherapeutics, Inc.
SABSW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $10.5K in total; no superinvestor holds it.
Other share classesSABS
Holders of 5% or more of SABSW
Holders whose latest Schedule 13D or 13G filing reports 5% or more of SAB Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of SAB Biotherapeutics, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on SAB Biotherapeutics, Inc., newest first.
No Schedule 13D or 13G filings on SAB Biotherapeutics, Inc. are on file.
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell SAB Biotherapeutics, Inc. shares.
No Form 144 notices for SAB Biotherapeutics, Inc. are on file.